Retrophin raises $25m to fund new deal, advance pipeline
This article was originally published in Scrip
Orphan disease-focused pharmaceutical company Retrophin raised $25 million from a private placement of stock and warrants to fund its obligations under a new licensing agreement and to advance its lead drug candidate RE-021 and other programs.
You may also be interested in...
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
The expectation of a big second quarter sales decline proved true, but the situation is improving. Meanwhile, Merck & Co. is advancing two vaccines and an antiviral against the novel coronavirus.
Sales were down in the second quarter to $5.07bn, primarily due to coronavirus-related impacts, but Gilead’s COVID-19 antiviral therapy remdesivir will boost revenues in the second half.